Vertex Pharmaceuticals received an upgrade from StockNews.com, moving from a “hold” to a “buy” rating. Other analysts have ...

In the latest market close, Vertex Pharmaceuticals (VRTX) reached $502.92, with a +1.51% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily loss of ...

This was the stock's second consecutive day of gains.

Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 5 years ago, it would be worth $253.80 today based on a ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Citi said SMid biotech sentiment has been more challenged than expected in early 2025, largely due to investor focus on ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Investing.com -- Vertex Pharmaceuticals Inc (NASDAQ: VRTX ).’s newly approved non-opioid pain medication, Journavx, has been included in UnitedHealth Group Inc (NYSE: UNH ).’s coverage, according to ...

Wall Street stocks closed sharply lower on Tuesday as Donald Trump's tariffs on Canadian, Mexican and Chinese imports came ...